RespirTech

What RespirTech does

RespirTech (legal entity: Respiratory Technologies, Inc.) is a Plymouth, Minnesota-based medical device company founded in 2004 and wholly owned by Koninklijke Philips N.V. since 2017. The company develops and distributes airway clearance therapy hardware — principally the Philips InCourage System, a high-frequency chest wall oscillation (HFCWO) vest device that uses a proprietary triangle waveform (covered by US Patent 6,958,046) to mobilize and clear excess lung secretions. Its portfolio also included the Philips Respironics CoughAssist T70 mechanical insufflation-exsufflation device until that line was discontinued in September 2023, with service and parts support continuing through October 1, 2028.

RespirTech sells through a prescription-based, payer-reimbursed distribution model: physicians prescribe its devices, the company coordinates insurance coverage with Medicare, Medicaid, the Veterans Health Administration, and commercial plans, and licensed respiratory therapists and registered nurses deliver devices to patients' homes and train them on use. The company maintains the world's largest bronchiectasis patient registry, with longitudinal outcomes data collected from over 25,000 patients since 2013, and runs dedicated outcomes programs for the general patient population and the VA.

The company serves four primary patient segments — adults with bronchiectasis (often comorbid with COPD), cystic fibrosis patients, patients with neuromuscular or neuromotor disorders such as ALS, muscular dystrophy, and cerebral palsy, and veterans with chronic respiratory disease — through referrals from pulmonologists, clinical educators, and patient advocacy outreach. Headcount is reported at 51-100 employees, and the business is wholly consolidated into Philips' Respiratory Care franchise.

Name

RespirTech

Legal name

Respiratory Technologies, Inc.

Website

https://respirtech.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

RespirTech is a Plymouth, Minnesota-based medical device company (wholly owned by Philips since 2017) that develops and distributes prescription-based high-frequency chest wall oscillation vest therapy for patients with bronchiectasis, cystic fibrosis, COPD, and neuromuscular respiratory conditions, supported by in-home training, insurance navigation, and the world's largest bronchiectasis outcomes registry.

Ownership category

akta.pro rank

Product category

Respiratory Medical Devices

akta.pro primary industry

Chest Physiotherapy & Airway Clearance Devices (PEP, Oscillatory PEP, HFCWO, Cough Assist) (HLAHAGAJ)

akta.pro secondary industries

Respiratory & Sleep Therapy Equipment (Oxygen, CPAP/BiPAP, Nebulizers) (HSABAKAD), Home Respiratory & Ventilator Care (Skilled) (HLADAFAI), Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)

Keywords

• Airway clearance therapy
• HFCWO vest therapy
• Respiratory medical devices
• Chronic respiratory care
• Durable medical equipment

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Medical Device Sales (HFCWO Vest Systems): Sale of Philips InCourage vest therapy systems and Philips Respironics CoughAssist T70 devices. Requires physician prescription and is typically covered by health insurance including Medicare, Medicaid, and commercial plans.
2. Equipment Rental and Supplies: Replacement accessories, repair parts, and supplies for existing devices. CoughAssist service and support continued through October 1, 2028 following September 2023 discontinuation.
3. Insurance Reimbursement: Revenue through insurance reimbursement from Medicare, Medicaid, Veterans Health Administration (VA), and commercial health insurance plans.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

RespirTech provides airway clearance therapy solutions, primarily the Philips InCourage HFCWO (high-frequency chest wall oscillation) vest therapy system, to patients with chronic respiratory conditions including bronchiectasis, cystic fibrosis, COPD, and neuromuscular disease. The company manages the full prescription-to-home-delivery workflow and wraps the device with a patient support program that includes in-home respiratory therapist setup, insurance coverage verification, and ongoing clinical follow-up. Its proprietary Triangle Waveform (US Patent 6958046) and Active Venting design differentiate the InCourage system from competing HFCWO vests on the market.

Product overview

RespirTech, a Philips company, offers a focused portfolio of airway clearance products and support services for patients with chronic respiratory conditions. The core product line includes the Philips InCourage System (high-frequency chest wall oscillation vest therapy using proprietary triangle waveform technology) and the now-discontinued Philips Respironics CoughAssist T70 (mechanical insufflation-exsufflation device). These devices are complemented by RespirTech's comprehensive patient support program, which provides insurance navigation, in-home training, and ongoing monitoring through the world's largest bronchiectasis patient registry. The company serves patients with bronchiectasis, COPD, cystic fibrosis, and neuromuscular disorders affecting respiratory function.

Differentiator

Problem solved

Functional benefit

Products and services

• Philips InCourage System High-frequency chest wall oscillation (HFCWO) vest therapy system that uses a proprietary Triangle Waveform (US Patent 6958046) and Active Venting technology to deliver air pulses that thin and mobilize airway secretions for patients with chronic respiratory conditions such as bronchiectasis, cystic fibrosis, COPD, and neuromuscular disease. Prescribed by clinicians, delivered to the home, and reimbursed through Medicare, Medicaid, Veterans Health Administration, and commercial payors.
• Philips Respironics CoughAssist T70 Mechanical insufflation-exsufflation device providing non-invasive airway clearance for patients with reduced ability to cough, particularly those with neuromuscular disease. Originally sold through RespirTech's prescription channel; new sales discontinued September 12, 2023, with RespirTech continuing service and support for existing patients through October 1, 2028.
• InCourage Comfort Vest Replacement vest accessory for the Philips InCourage HFCWO system, available in multiple sizes and used during therapy sessions to deliver chest wall oscillation comfortably across patient body types.
• RespirTech Patient Support Program Comprehensive patient support service for individuals prescribed airway clearance therapy, including in-home device setup and training by respiratory therapists, insurance coverage verification and prior authorization assistance, ongoing adherence and clinical follow-up, and dedicated patient advocates. Designed to improve real-world adherence and outcomes for patients on daily HFCWO therapy.

Quantifiable outcome

• Yearly rate of hospitalization decreased by 62% after 12 months of InCourage vest therapy
• +9 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• Royal Philips N.V.coreOthersRespirTech was acquired by Philips in 2017. As a Philips company, RespirTech helps people with chronic respiratory conditions through Philips InCourage vest therapy and Philips Respironics products. The acquisition strengthened the goal of improving quality of life for patients with respiratory complications.

Scale indicators9 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Diversified medical device major with respiratory and patient monitoring solutions that intersect with RespirTech's outcomes-tracking and chronic care patient base.
• Drägerwerk: Large medical technology company with a strong portfolio in ventilation and airway management. Operates broadly in hospital and home respiratory care where RespirTech's neuromuscular and COPD patients are also served.
• Koninklijke Philips N.V. Parent company of RespirTech and the largest competing respiratory franchise globally (Respironics CPAP/BiPAP, hospital ventilation). While Philips owns RespirTech, adjacent internal product lines overlap in patient populations and prescribers, making it both parent and partial competitor.
• Fisher & Paykel Healthcare: Global leader in respiratory humidification, CPAP, and nasal high-flow therapy. Competes for the chronic respiratory patient wallet and prescriber relationships, particularly in COPD and neuromuscular overlap segments.
• Teleflex: Manufacturer of airway management devices (endotracheal tubes, laryngeal masks, suction). Adjacent in the airway clearance care pathway and shares hospital and home respiratory prescribers with RespirTech.

Direct peers

• Vyaire Medical: Respiratory care device manufacturer offering airway clearance and ventilation products, including competing solutions in hospital and home respiratory care. Comparable in airway clearance focus and payor-dependent revenue model.
• Baxter International (Hill-Rom Respiratory Care): Through the Hill-Rom acquisition, Baxter offers The Vest airway clearance system — a long-standing HFCWO competitor. Overlapping patient populations and reimbursement infrastructure make this the most direct competing device franchise.
• Electromed: Direct competitor in HFCWO vest therapy with the SmartVest system targeting bronchiectasis, CF, COPD, and neuromuscular patients. Closest pure-play comparable to RespirTech's InCourage system in indications, channel, and payor mix.

Emerging players

• International Biophysics: Smaller HFCWO competitor with a focus on affordability and emerging markets. Represents the lower-cost disruptive end of the same vest therapy category RespirTech competes in.
• Monaghan Medical: Specialises in oscillatory PEP devices (Acapella) and positive expiratory pressure airway clearance — a non-vest but directly competing airway clearance modality for bronchiectasis, CF, and COPD patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/respirtech
• LinkedInlinkedin.com/company/147965

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RespirTech